Maruha Nichiro Announces Strategic Investment and Development Collaboration with Umami Bioworks on the Development of Cultivated Seafood in Japan

The Japanese fishing giant will access Umami Bioworks’ cell cultivation development and manufacturing platform as part of a collaboration to develop and commercialize cultivated seafood production in Japan and beyond

Umami Bioworks (formerly known as Umami Meats), a Singapore-headquartered company developing the development and manufacturing system for producing cultivated seafood, announced their official collaboration with Japan’s largest fishing company, Maruha Nichiro (TYO: 1333). This is the first time a Japanese seafood company has chosen to invest in and collaborate with a foreign cell-cultivated seafood company.
Background:
While the demand for seafood has been growing worldwide, supply shortages are becoming a huge risk due to factors like overfishing and marine pollution. These challenges have led to decreasing wild-catch volumes, as well as health concerns around microplastics and heavy chemicals in seafood. In particular, Japan’s self-sufficiency rate for seafood remains at a low level of 55%, while the domestic wild-catch volumes have decreased approximately 65% over the last 30 years. This poses great risks not only to consumers, but also to the Japanese seafood industry, fishermen, and the overall economy.
Under such circumstances, cultivated products have attracted worldwide attention, with global investment in cultivated products reaching $2.8 billion in 2022. However, many Japanese companies are still lagging behind in participating actively in this industry. Maruha Nichiro has stepped up as a leader to ensure a sustainable supply of seafood worldwide, and to make its first formal investment in cellular agriculture with the aim of laying the foundation for Japan’s cell-cultivated seafood industry.
Umami Bioworks and Maruha Nichiro will be working to build the infrastructure of Japan’s cultivated seafood industry together in this partnership. The strategic investment from Maruha Nichiro will help accelerate Umami’s development progress. The two companies will also carry out a multi-faceted collaboration to accelerate the path to cultivated seafood commercialization, particularly in novel ETP (endangered, threatened and protected) species that have global relevance.
With this investment, Umami Bioworks will be able to expedite their long-term plan of building a research and commercial team in Japan. In turn, Maruha Nichiro will have a third method of sustainable production, other than fishing and aquaculture, for increasingly scarce seafood species.
By establishing a production pipeline of cell-cultivated products for the Japanese market, both companies will develop a foundation for cell-cultivated in Japan and provide the market with a sustainable and stable supply of locally produced seafood.
Mihir Pershad, CEO of Umami Bioworks, “Our seminal partnership with Maruha Nichiro, a global leader in crafting beloved food products, is a pivotal step in achieving our mission of addressing the challenge of feeding a growing global population while minimizing environmental impact. We have the development and production technology, but we require experienced partners with global reach that can help us manufacture and deliver cultivated products to consumers. Through collaborations with industry leaders like Maruha Nichiro, we can leverage our technology expertise to support co-development of delicious, nutritious, and appealing consumer products that secure a healthier and more sustainable food future for the world.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”